|
|
525 Chesapeake Drive
Redwood City, CA 94063 United States
phone:(650) 388-8222
fax:650-474-2900
|
|
| Symbol |
Private |
| Founded |
2005 |
| Employees |
|
|
|
| www.myoscience.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Develops and commercializes technology driven products for aesthetic medicine. |
|
| Management |
| Bob Curtis ? President & CEO; Matt Franklin ? CFO; Kristine Tatsutani, PhD ? VP Clinical & Scientific Development; Mike Fourkas ? VP Product Development & Operations; Tracey Henry ? Director Regulatory/Quality/Clinical Compliance; Kevin Fitzgerald ? Sr. Market Development Manager |
| |
|
|
| |
|
| Keywords |
| aesthetics, dermatology, plastic surgery, frown lines, forehead lines, crow�s feet, facial rejuvenation, aesthetic medicine |
|
|
|
| Description |
|
MyoScience Inc., a medical device company founded in 2005, is in clinical development of a non-toxic alternative to injectable neurotoxins (Botox Cosmetic�, Dysport�, and others) for the treatment of dynamic facial wrinkles (forehead lines, frown lines between the brows, and crow's feet). |
|
| Products / Services |
The MyoScience product, a medical device that employs a reposable business model, consists of a low cost, self-contained, reusable handpiece plus sterile single-use kits for the treatment of different facial areas.
|
|
| Technology / Differentiation |
MyoScience?s technology offers customers:
Minimally invasive/non-surgical procedure for treating dynamic facial wrinkles
Non-toxic mechanism of action, attractive to neurotoxin averse patients
Market & physician practice expansive, private pay procedure with excellent MD practice and company economics
Treatment that does not employ injectable drugs or biologics
Reposable business model with no large $ capital equipment purchase |
|
| Market / Customers |
MyoScience will target high volume aesthetic physician practices, primarily Dermatologists and Plastic Surgeons and will ultimately expand into other MD specialties where aesthetics is an important business segment.
|
|
| Competitors / Substitutes / Alternatives |
The only alternatives currently available for treating dynamic facial wrinkles are injectable neurotoxins and cosmetic surgery.
There are no therapies widely available for those patients averse to neurotoxins ? a population estimated to be larger than the current neurotoxin treated demographic.
|
|
| Funding |
Current Investors: DeNovo Ventures, Accuitive Medical Ventures, Saratoga Ventures, Nexus Medical Partners, Medicis Capital.
Raising $12M in C round financing for commercial device development and OUS and US regulatory approvals with wrinkle claims |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members